Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03291223 · ClinicalTrials.gov registry record

Gaucher Disease Outcome Survey (GOS)

A clinical trial of Gaucher Disease, sponsored by Shire.

Recruiting
Registry status
1,257
Enrollment target
1
Study location

NCT03291223 is a study of Gaucher Disease that is actively recruiting participants, run by Shire. The registered enrollment target is 1,257 participants, above the 962-participant average among 13 other Gaucher Disease trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03291223, a study of Gaucher Disease, is actively recruiting participants, sponsored by Shire.

RECRUITING
Registry status
1,257 participants
Enrollment target
1
Study location

Study Summary

The Gaucher Outcomes Survey (GOS) is an ongoing observational, international, multi-center, long-term Registry of Patients with Gaucher Disease irrespective of their treatment status or type of treatment received. No experimental intervention is involved. Patients undergo clinical assessments and receive care as determined by the patients' treating physician. The objectives of the registry include to evaluate the safety and long-term effectiveness of velaglucerase alfa, to characterize patients receiving velaglucerase alfa or other Gaucher Disease-specific treatments, to gain a better understanding of the natural history of GD and to serve as a database for evidence-based management of Gaucher Disease over time in real-life clinical practice.

Conditions Studied

Study Locations (1)

Massachusetts

  • Central Contact - Lexington

Trial Details

FieldValue
Enrollment Target 1,257 participants
Start Date 2010-07-27
Est. Completion 2026-09-30

Sponsor

Shire

245 total trials

What the Registry Record Tells You About NCT03291223

The ClinicalTrials.gov registry entry for NCT03291223 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,257 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 962-participant average among 13 other Gaucher Disease trials with a reported enrollment target (31% higher). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gaucher Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03291223 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03291223 about?

NCT03291223 is a clinical study titled "Gaucher Disease Outcome Survey (GOS)". The Gaucher Outcomes Survey (GOS) is an ongoing observational, international, multi-center, long-term Registry of Patients with Gaucher Disease irrespective of their treatment status or type of treatment received. No experimental intervention is involved. Patients undergo clinical assessments and re...

What is the current status of trial NCT03291223?

This trial is currently recruiting. The enrollment target is 1,257 participants. The study started on 2010-07-27. Estimated completion is 2026-09-30.

What conditions does trial NCT03291223 study?

This clinical trial studies the following conditions: Gaucher Disease.

Who is sponsoring clinical trial NCT03291223?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03291223 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gaucher Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.